{"title":"Xanomeline-trospium significantly improves cognition in acute schizophrenia","authors":"","doi":"10.1002/pu.31284","DOIUrl":null,"url":null,"abstract":"<p>The drug combining xanomeline and trospium chloride (Cobenfy®) significantly improved cognition relative to placebo in cognitively impaired adults with acute schizophrenia, a study based on data from two Phase 3 trials has found. Changes in cognition were not significantly correlated with changes in symptoms of schizophrenia, study investigators reported. Study results were published online Dec. 11, 2024, in the <i>American Journal of Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 4","pages":"1-5"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The drug combining xanomeline and trospium chloride (Cobenfy®) significantly improved cognition relative to placebo in cognitively impaired adults with acute schizophrenia, a study based on data from two Phase 3 trials has found. Changes in cognition were not significantly correlated with changes in symptoms of schizophrenia, study investigators reported. Study results were published online Dec. 11, 2024, in the American Journal of Psychiatry.